Ubiquitin-like Molecule ISG15 Acts as an Immune Adjuvant to Enhance Antigen-specific CD8 T-cell Tumor Immunity

Molecular Therapy

Volumn 23, Issue 10, 2015, Pages 1653-1662

  Villarreal, Daniel O ^a   Wise, Megan C ^a   Siefert, Rebekah J ^a,b   Yan, Jian ^c   Wood, Laurence M ^d   Weiner, David B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Inovio Pharmaceuticals   (United States)

^d TEXAS TECH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERFERON STIMULATING GENE 15 PROTEIN; UNCLASSIFIED DRUG; ANTIGEN; CANCER VACCINE; CYTOKINE; DNA VACCINE; EPITOPE; ISG15 PROTEIN, HUMAN; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; PROTEIN E7; UBIQUITIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; MALE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; TUMOR IMMUNITY; TUMOR VOLUME; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; DISEASE MODEL; FEMALE; GENE EXPRESSION; GENE VECTOR; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; LYMPHOCYTE DEPLETION; METABOLISM; MOLECULAR GENETICS; MUTATION; NEOPLASMS; PATHOLOGY; SEQUENCE ALIGNMENT; TRANSGENIC MOUSE; TUMOR CELL LINE;

ADJUVANTS, IMMUNOLOGIC; ADOPTIVE TRANSFER; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOKINES; DISEASE MODELS, ANIMAL; EPITOPES, T-LYMPHOCYTE; FEMALE; GENE EXPRESSION; GENETIC VECTORS; HUMANS; IMMUNIZATION; LYMPHOCYTE DEPLETION; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASMS; PAPILLOMAVIRUS E7 PROTEINS; SEQUENCE ALIGNMENT; UBIQUITINS; VACCINES, DNA;

EID: 84943583779     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.120     Document Type: Article

References (42)

1. Slaney, CY, Kershaw, MH and Darcy, PK (2014). Trafficking of T cells into tumors. Cancer Res 74: 7168-7174.
2. Mellman, I, Coukos, G and Dranoff, G (2011). Cancer immunotherapy comes of age. Nature 480: 480-489.
3. Gajewski, TF, Meng, Y, Blank, C, Brown, I, Kacha, A, Kline, J et al. (2006). Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 213: 131-145.
4. Jensen, BA, Steffensen, MA, Nielsen, KN, Christensen, JP, Thomsen, AR and Holst, PJ (2014). Co-expression of tumor antigen and interleukin-2 from an adenoviral vector augments the efficiency of therapeutic tumor vaccination. Mol Ther 22: 2107-2117.
5. Villarreal, DO, Wise, MC, Walters, JN, Reuschel, EL, Choi, MJ, Obeng-Adjei, N et al. (2014). Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res 74: 1789-1800.
6. Campbell, JA and Lenschow, DJ (2013). Emerging roles for immunomodulatory functions of free ISG15. J Interferon Cytokine Res 33: 728-738.
7. Knight, E Jr and Cordova, B (1991). IFN-induced 15-kDa protein is released from human lymphocytes and monocytes. J Immunol 146: 2280-2284.
8. Recht, M, Borden, EC and Knight, E Jr (1991). A human 15-kDa IFN-induced protein induces the secretion of IFN-gamma. J Immunol 147: 2617-2623.
9. D'Cunha, J, Knight, E Jr, Haas, AL, Truitt, RL and Borden, EC (1996). Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad Sci USA 93: 211-215.
10. Bogunovic, D, Byun, M, Durfee, LA, Abhyankar, A, Sanal, O, Mansouri, D et al. (2012). Mycobacterial disease and impaired IFN-? immunity in humans with inherited ISG15 deficiency. Science 337: 1684-1688.
11. Loeb, KR and Haas, AL (1992). The interferon-inducible 15-kDa ubiquitin homolog conjugates to intracellular proteins. J Biol Chem 267: 7806-7813.
12. Lenschow, DJ, Giannakopoulos, NV, Gunn, LJ, Johnston, C, O'Guin, AK, Schmidt, RE et al. (2005). Identification of interferon-stimulated gene 15 as an antiviral molecule during Sindbis virus infection in vivo. J Virol 79: 13974-13983.
13. Sloper-Mould, KE, Jemc, JC, Pickart, CM and Hicke, L (2001). Distinct functional surface regions on ubiquitin. J Biol Chem 276: 30483-30489.
14. Shedlock, DJ, Aviles, J, Talbott, KT, Wong, G, Wu, SJ, Villarreal, DO et al. (2013). Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola. Mol Ther 21: 1432-1444.
15. Gendron, KB, Rodriguez, A and Sewell, DA (2006). Vaccination with human papillomavirus type 16 E7 peptide with CpG oligonucleotides for prevention of tumor growth in mice. Arch Otolaryngol Head Neck Surg 132: 327-332.
16. Peng, S, Trimble, C, Alvarez, RD, Huh, WK, Lin, Z, Monie, A et al. (2008). Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects. Gene Ther 15: 1156-1166.
17. Morrow, MP, Yan, J and Sardesai, NY (2013). Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer. Expert Rev Vaccines 12: 271-283.
18. Bagarazzi, ML, Yan, J, Morrow, MP, Shen, X, Parker, RL, Lee, JC et al. (2012). Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 4: 155ra138.
19. Maldonado, L, Teague, JE, Morrow, MP, Jotova, I, Wu, TC, Wang, C et al. (2014). Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci Transl Med 6: 221ra13.
20. Olson, JA, McDonald-Hyman, C, Jameson, SC and Hamilton, SE (2013). Effector-like CD8? T cells in the memory population mediate potent protective immunity. Immunity 38: 1250-1260.
21. Hansen, SG, Ford, JC, Lewis, MS, Ventura, AB, Hughes, CM, Coyne-Johnson, L et al. (2011). Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473: 523-527.
22. Sallusto, F, Geginat, J and Lanzavecchia, A (2004). Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22: 745-763.
23. Huster, KM, Stemberger, C and Busch, DH (2006). Protective immunity towards intracellular pathogens. Curr Opin Immunol 18: 458-464.
24. Seder, RA and Ahmed, R (2003). Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol 4: 835-842.
25. van Duikeren, S, Fransen, MF, Redeker, A, Wieles, B, Platenburg, G, Krebber, WJ et al. (2012). Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors. J Immunol 189: 3397-3403.
26. Bracci, L, Moschella, F, Sestili, P, La Sorsa, V, Valentini, M, Canini, I et al. (2007). Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res 13(2 Pt 1): 644-653.
27. Yan, J, Reichenbach, DK, Corbitt, N, Hokey, DA, Ramanathan, MP, McKinney, KA et al. (2009). Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine 27: 431-440.
28. Angelosanto, JM, Blackburn, SD, Crawford, A and Wherry, EJ (2012). Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection. J Virol 86: 8161-8170.
29. Lamikanra, A, Pan, ZK, Isaacs, SN, Wu, TC and Paterson, Y (2001). Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site. J Virol 75: 9654-9664.
30. Indrová, M, Bieblová, J, Bubeník, J and Reinis, M (2008). IL-12 immunotherapy of minimal residual disease in murine models of HPV16-associated tumours: induction of immune responses, cytokine production and kinetics of immune cell subsets. Int J Oncol 32: 499-507.
31. Khairuddin, N, Blake, SJ, Firdaus, F, Steptoe, RJ, Behlke, MA, Hertzog, PJ et al. (2014). In vivo comparison of local versus systemic delivery of immunostimulating siRNA in HPV-driven tumours. Immunol Cell Biol 92: 156-163.
32. Plotkin, SA (2010). Correlates of protection induced by vaccination. Clin Vaccine Immunol 17: 1055-1065.
33. Bogunovic, D, Boisson-Dupuis, S and Casanova, JL (2013). ISG15: leading a double life as a secreted molecule. Exp Mol Med 45: e18.
34. Wang, W, Zhang, M, Xiao, ZZ and Sun, L (2012). Cynoglossus semilaevis ISG15: a secreted cytokine-like protein that stimulates antiviral immune response in a LRGG motif-dependent manner. PLoS One 7: e44884.
35. Zhang, X, Bogunovic, D, Payelle-Brogard, B, Francois-Newton, V, Speer, SD, Yuan, C et al. (2015). Human intracellular ISG15 prevents interferon-?/? over-amplification and auto-inflammation. Nature 517: 89-93.
36. Domingos-Pereira, S, Decrausaz, L, Derré, L, Bobst, M, Romero, P, Schiller, JT et al. (2013). Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice. Mucosal Immunol 6: 393-404.
37. Rahimian, S, Fransen, MF, Kleinovink, JW, Christensen, JR, Amidi, M, Hennink, WE et al. (2015). Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation. J Control Release 203: 16-22.
38. Song, YC, Cheng, HY, Leng, CH, Chiang, SK, Lin, CW, Chong, P et al. (2014). A novel emulsion-type adjuvant containing CpG oligodeoxynucleotides enhances CD8+ T-cell-mediated anti-tumor immunity. J Control Release 173: 158-165.
39. Villarreal, DO, Walters, J, Laddy, DJ, Yan, J and Weiner, DB (2014). Multivalent TB vaccines targeting the esx gene family generate potent and broad cellmediated immune responses superior to BCG. Hum Vaccin Immunother 10: 2188-2198.
40. Lin, KY, Guarnieri, FG, Staveley-O'Carroll, KF, Levitsky, HI, August, JT, Pardoll, DM et al. (1996). Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56: 21-26.
41. Gunn, GR, Zubair, A, Peters, C, Pan, ZK, Wu, TC and Paterson, Y (2001). Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 167: 6471-6479.
42. Stephen, TL, Rutkowski, MR, Allegrezza, MJ, Perales-Puchalt, A, Tesone, AJ, Svoronos, N et al. (2014). Transforming growth factor ?-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression. Immunity 41: 427-439.